![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Impax Pulls 35M Cholesterol Capsules Over Incorrect Labeling
Impax Pulls 35M Cholesterol Capsules Over Incorrect Labeling
![](https://www.fdanews.com/ext/resources/test/Drug-Images3/RedYellow_BlueWhite_Pills.jpg?t=1433969395&width=430)
Impax Laboratories and a unit of AmerisourceBergen have initiated two recalls of fenofibrate cholesterol drugs due to incorrect labeling.
The nationwide recalls, initiated last March, were deemed Class 2 last week. The affect 21 lots, according to an April 14 FDA Enforcement Report. The recall affects the 500- and 134-mg dosages.
Approximately 35 million capsules are involved in the recall.
Upcoming Events
-
21Oct